Scailyte Announces Jan Lichtenberg, CEO at inSphero, as a Member of the Board of Directors

BASEL, Switzerland, May 9, 2023 (Newswire.com) - Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is proud to announce the appointment of Jan Lichtenberg to its Board of Directors.

Jan Lichtenberg, Ph.D., is Co-Founder and CEO of Swiss- and US-based InSphero Inc., the world-leading biotech specialising in 3D cell-culture technologies for discovery and safety. With over 20 years of experience in the life sciences and expertise in engineering and laboratory automation, Jan brings a wealth of knowledge and leadership to Scailyte's board.

Jan earned his Ph.D. in Microtechnology and Microfluidics from the University of Neuchâtel, Switzerland, and has a track record of successfully leading and growing biotech companies. His experience includes VP R&D and Product Management positions at Hocoma AG (medical robotics) and Uwatec (microelectronics).

Jan's comment: "I am excited to join the Board of Scailyte, which has impressed me with their unique technology platform and deep understanding of the challenges of analyzing complex biological data. The combination of single-cell genomics and data analysis has the potential to revolutionize our understanding of biology and disease, and to enable the development of new diagnostics and therapies that are tailored to the individual characteristics of patients. Helping to achieve this is a great honor."

Peter Nestorov, Co-Founder and CEO of Scailyte, is similarly excited: "Jan is a passionate and very experienced entrepreneur who brings in a lot of experience related to developing and commercializing life science products. In particular, Jan's experience in establishing a successful business model embedded in drug discovery is highly relevant to Scailyte and can help us to achieve commercial success and advance Scailyte to becoming a global biomarker discovery leader."

Jan will be taking the place of Jean-Pierre Rosat, General Partner at 4FOX ventures. Jean-Pierre has provided valuable strategic insights and guidance to the company and brought in his network of leading global experts. Jean-Pierre will continue to support the company as a Board Observer.

With Lichtenberg's appointment, Scailyte has further strengthened its Board of Directors with an experienced industry leader who will play an important role in shaping the company's future. The company remains committed to advancing the field of precision medicine with single-cell technologies, artificial intelligence, and multi-omics analysis.

About Scailyte

Scailyte is an ETH Zürich spin-off with a proprietary artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution ScaiVision® provides unprecedented insight into the disease and patients' biology and enables the discovery of new clinically-relevant biomarker signatures, with a focus on oncology and immunology. 

Scailyte's proprietary data analysis platform ScaiVision® associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically relevant applications of Scailyte's platform ScaiVision® have been demonstrated in various projects in oncology and immunology. Additionally, Scailyte leverages a broad network of top clinicians to identify clinical indications with high unmet clinical needs and collaborates with global pharmaceutical and biotech companies to translate novel biomarkers into ultra-sensitive companion diagnostics (CDx) or IVD assays. 

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

Scailyte™ and ScaiVision™ are registered trademarks proprietary to Scailyte AG.

Source: Scailyte